All Publications
By running clinical trials with limited duration of therapy, we could describe the patterns of immune reconstitution after treatment cessation.
We used next-generation sequencing to quantify myeloma disease burden before and after autologous stem cell transplantations providing a benchmark to study immunotherapeutic alternatives to transplantation.
A panel of CoMMit experts put together a number of practical recommendations to reduce the impact of infections in the outcomes of patients with MM receiving bispecific antibodies or CAR T-cells.
Using data from MASTER enriched by a real-world dataset we framed the concept of “MRD-P”, the increase in MRD burden without traditional criteria for progression and describe its prognostic implication.
In another collaboration with GRIFFIN investigators, we describe the success of stem cell mobilization after quadruplet therapy.
We collaborated with investigators from the GRIFFIN trial to join data from GRIFFIN + MASTER and describe the outcomes of patients with high-risk myeloma treated with quadruplet therapy and autologous stem cell transplantation.
Using data from MASTER enriched by a real-world dataset, we used rigorousn methodology to determine the best MRD endpoint for treatment cessation in NDMM.
Longer follow up of the MASTER trial shows the outcomes of patients who achieved MRD negativity and discontinued therapy.
The MASTER trial was among the first to use MRD to modulate therapy in newly diagnosed multiple myeloma.
We demonstrated the safety of combining carfilzomib with melphalan as conditioning regimen for autologous stem cell transplantation, followed by carfilzomib maintenance.